MSc Cancer Immunotherapy
Course overview
The London Metropolitan University MSc Cancer Immunotherapy provides you with an understanding of conventional cancer therapies such as surgery, radiation, and chemotherapy, as well as the fields of cancer biology and oncology. The curriculum will provide you with a deep understanding of the molecular targets of anticancer drugs and the evolution of drug therapies.
The programme also covers new areas of immunotherapy, including monoclonal antibodies, DNA vaccines, and adoptive T-cell therapy. The course is taught by experienced researchers from the Cellular and Molecular Immunology Research Centre. The final assessment is a research project with an oral defence.
Entry requirements
Candidates are required to submit a personal statement in which they discuss their reasons for applying for the course and other relevant information regarding their studies. A relevant academic and/or employer reference is also required. Students have the option to upload their CV along with their applications to demonstrate their work experience.
Grade Requirements:
- Applicants should have a UK first degree (or an equivalent qualification) of at least a lower second-class (2:2).
- Relevant subjects include pharmacology, biomedical science, biological science, or medical genetics.
English Proficiency:
- IELTS overall score of 6.5 with a minimum of 6.0 in all sections.
- Other equivalent qualifications such as TOEFL and PTE are also accepted.
Scholarships
Chevening Scholarships
Career opportunities
Graduates of this programme work as:
- Medical Scientist
- Clinical Scientist
- Immunologist
- Biomedical Scientist
- Pharmacologist
Cost of study
The annual tuition fee for the MSc Cancer Immunotherapy at London Metropolitan University is £20,000 for international students.
Admission
Students can submit their applications for this course directly to the university. Please speak to our trained counsellors for help.
Ready to start?
Book a free consultation and we'll map your fastest route to your place.